Toxicity aspects – Talk Bio

Elion nets $81M to fund development of antifungal with lower toxicity risks

10 months ago talkbio0Tagged Antifungal Agents, Elion, Lower - spatial qualifier, Risk, Toxicity aspects

Antifungal Agents, Lower – spatial qualifier, Toxicity aspects, Risk, Elion

Biomea’s Early-Stage Diabetes Drug Placed on Full Clinical Hold, Stock Plummets

11 months ago talkbio0Tagged Biomea, crash, Diabetes, Liver, Menin Inhibitor BMF-219, Study on Hold, Toxicity aspects, United States Food and Drug Administration

Biomea, diabetes, clinical hold, FDA, BMF-219, liver toxicity, stock crash

Tango Pauses Clinical Trials of Promising Solid Tumor Treatment Due to Liver Toxicity Concerns

11 months ago talkbio0Tagged ARNT gene, aspects of adverse effects, Cancer Research, Clinical Trials, Drug Development, Liver, solid tumor treatment, Toxicity aspects

Tango Therapeutics, solid tumor treatment, clinical trials, liver toxicity, drug development, cancer research, treatment side effects, patient safety.

Brukinsa by BeiGene Secures FDA Approval for Follicular Lymphoma Amid Imbruvica Setbacks

1 year ago talkbio0Tagged Accelerated, Antibodies, Bispecific, Approved, BeiGene, Brukinsa, Chimeric Antigen Receptor T-cells, Clinical Trials, Combined Modality Therapy, competition, Disease Progression, Gazyva, Lymphoma, Follicular, obinutuzumab, ORR, Overall response rate, Rosewood, Toxicity aspects, United States Food and Drug Administration, zanubrutinib

Brukinsa (zanubrutinib), BeiGene, FDA approval, follicular lymphoma, accelerated approval, obinutuzumab (Gazyva) combination therapy, ROSEWOOD trial, overall response rate (ORR), disease progression or unacceptable toxicity, competition with CAR-T cell therapies/ bispecific antibodies